VEGFA and choroidal neovascularization: Registrational trials, randomized control trials (RCT), meta‐analyses and observational studies have confirmed vascular endothelial growth factor (VEGF) inhibitors as the first‐line treatment for myopic choroidal neovascularization (mCNV) with better outcomes than previous treatments such as photodynamic therapy (PDT) or laser photocoagulation (Gharbiya et al.